Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia

Samankaltaisia teoksia

• Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
  Tekijä: Christophe Willekens, et al.
  Julkaistu: (2016-03-01)
• Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia
  Tekijä: Pierre Peterlin, et al.
  Julkaistu: (2015-05-01)
• Dexamethasone in hyperleukocytic acute myeloid leukemia
  Tekijä: Sarah Bertoli, et al.
  Julkaistu: (2018-06-01)
• Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia
  Tekijä: Thomas Prebet, et al.
  Julkaistu: (2014-10-01)
• Secondary acute myeloid leukemia: time to turn the page
  Tekijä: Christian Récher
  Julkaistu: (2023-07-01)